Springer Nature’s Chief Publishing Officer provides an insight into the transition to open access publishing following their publication of 1 million open access articles.
Publisher of Science journals update their Green open access policy for authors of research funded by cOAlition S organisations to allow Plan S compliance.
Learn more about this useful tool for checking compliance when publishing cOAlition S funded research articles.
Find out more about Springer Nature’s latest open access publishing options – and the concerns that some have raised.
Open access across the globe: our summary of the second Biomedical Transparency Summit series webinar
Find out more about what was covered during the second 2021 webinar from the Center for Biomedical Research Transparency.
cOAlition S Rights Retention Strategy aims to safeguard researchers’ intellectual ownership, enabling embargo-free sharing of research in online repositories.
From 2022, journals will need to follow cOAlition S price transparency requirements to get paid. Find out more about the frameworks and potential benefits here.
Following a public consultation, updated cOAlition S guidance relaxes the criteria for transformative journals, prompting commitments from further journals.
Find out more about the requirements cOAlition S plans to set for ‘transformative journals’.
Following the revised guidance on Plan S, Bernd Pulverer questions whether cOAlition S is making the most of the opportunity to push for open science.
Article processing charges are increasing, but a recent study finds that higher charges seem to attract rather than deter authors from submitting to open access journals.
ISMPP’s first white paper, ‘A multistakeholder discussion on open access and medical publishing’ is now available.
Missed the 15th Annual Meeting of ISMPP? Read our meeting report to get up to speed!
A recent article from The Chronicle of Higher Education discusses the potential benefits associated with journals that are established by funding bodies.
Feedback on the implementation guidance for Plan S highlights key themes for consideration.
Many public funders have mandated open access to their research and support Plan S. Should pharmaceutical companies follow suit?